FDA Open To Revising Guidance On Drug-Induced Liver Injury
This article was originally published in Pharmaceutical Approvals Monthly
Good drugs can be held responsible for bad things happening to the liver if sponsors do not fully explore alternate explanations for liver toxicities that turn up in a clinical trial, cautions John Senior, associate director for science in CDER’s Office of Surveillance and Epidemiology.
You may also be interested in...
March event will look at best ways to detect and assess drug liver injury causation as agency mulls reopening the 2009 final guidance.
Risk of drug-induced injury is likely to complicate an Aug. 5 advisory committee review of Otsuka’s kidney drug tolvaptan.
A March stakeholder conference is set to consider questions unresolved by the agency's two-year-old guidelines.